DIKUL - logo
Narodna in univerzitetna knjižnica, Ljubljana (NUK)
Naročanje gradiva za izposojo na dom
Naročanje gradiva za izposojo v čitalnice
Naročanje kopij člankov
Urnik dostave gradiva z oznako DS v signaturi
  • Intermitentno ciklično zdravljenje osteoporoze z etidronatom = Intermittent cyclical etidronate treatment of osteoporosis
    Kocijančič, Andreja, 1942-2021 ...
    Background. Etidronate has been used for the treatment of Paget's disease for s long time, its use in the treatment of osteoporosis is being reported more recently. The authors report on a ... randomized, double blind, placebo - controled clinical trial in which etidronate was used in 90 postmenopausal osteoporotic women. Methods. The patients were randomly assigned to a group taking 400 mg etidronate daily for two weeks, followed by 10 weeks with 1000 mg of calcium per day, and to a control group with the same regimen, where etidronate was replaced by placebo. The cycles were repeated every three months during one year. The effects were evaluated by measurement of bone mineral density (BMD) by dual energy x-ray absorptiometry (DEXA). X-ray was performed before and after the study to determine the vertebral fractures. Results. BMD significantly increased in the group treated with etidronate and calcium (5.0% +- 0.6; p<0.05), while in the placebo treated only with calcium the increase (2.5% +- 0.7) was not significant. In the treated group a marker of bone resorption, urinary hydroxyproline (adjusted for urinary creatinine) significantly decreased from 18.5 +- 1.1 micromol/mmol creatinine before therapy to 12.0 +-1.3 micromol/mmol creatinine after therapy. Serum osteocalcin, as a marker of bone formation, also significanty decreased from 19.1 nmol/L +- 1.5 to 11.8 nmol/L +- 1.2. No significant changes were detectedin the control group. Number of x-ray detected vertebral fractures after one year increased in both groups with only differences between the treated and the placebo group. There were no serious side effects of the treatment during the study. Conclusion. Afer one year of treatment of osteoporosis in postmenopausal women with etidronate and calcium the BMD significantly increases.
    Vir: Zdravniški vestnik : glasilo Slovenskega zdravniškega društva = Slovenian medical journal = journal of Slovenian Medical Association. - ISSN 1318-0347 (Letn. 69, št. 2, feb. 2000, str. 87-91)
    Vrsta gradiva - članek, sestavni del
    Leto - 2000
    Jezik - slovenski
    COBISS.SI-ID - 11185625

Vnos na polico